Roche Cedes CEDIA DOA Reagents, Seals Corange Deal March 5
This article was originally published in The Gray Sheet
Roche is negotiating with potential buyers of Boehringer Mannheim's Closed Enzyme Donor Immuno Assay (CEDIA) reagents for drugs-of-abuse (DOA) testing to comply with conditions of a Feb. 24 Federal Trade Commission settlement. The FTC settlement cleared the way for Roche's $10.2 bil. acquisition of Corange, the parent company of Boehringer Mannheim and DePuy.
You may also be interested in...
Roche Diagnostics will bolster its genetic research efforts by adding a 100-person genomics staff as it seeks to capitalize on advances being made in the genomics field by shifting its R&D focus from clinical chemistry to molecular genetics.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.